

6. Rue Ibn Ennafis - Z.I. Lac 3 Tunisie Tél. : 71 182 500 - Fax : 71 182 250 www.biomaghreb.com

CE

GPT - ALAT

Kinetic Test. IFCC Without Pyridoxal phosphate

Quantitative determination of alanine amino transferase activity (EC 2.6.1.2) in human serum

IN VITRO DIAGNOSTIC USE



| REF 11015 | 20 x 3 ml (60 T) | R1: 1 x 65 ml | R2: 20 Lyophilisates |
|-----------|--------------------|----------------------|----------------------|
| REF 11022 | 10 x 10 ml (100 T) | R1: 1 x110 ml | R2: 10 Lyophilisates |
| REF 11039 | 10 x 3 ml (30 T) | R1: 1 x 35 ml | R2: 10 Lyophilisates |
| REF 11046 | 2 x 110 ml (220 T) | R1: 2 x110ml | R2: 2 Lyophilisates |

CLINICAL SIGNIFICANCE

ALAT (alanine amino-transferase) formerly known as Glutamic Pyruvic Transaminase (GPT) is an enzyme found mainly in liver cells, and to a lesser extent in kidney, heart, and muscle cells. The measurement of ALAT activity allows the detection of liver damage. When the liver is damaged, ALAT is released into the bloodstream in patients with cirrhosis, hepatitis, cancer and jaundice due to biliary congestion). In general, ALAT activity values are compared with the activities of other enzymes such as alkaline phosphatase (PAL), aspartate aminotransferase (ASAT) and bilirubin to accurately define the origin of liver damage.

PRINCIPLE

The kinetic determination of ALAT activity is based on the method developed by Wrobleski and Ladue, and optimized by Henry and Bergmeyer.

The reaction is initiated by adding the sample to the reagent according to the following reaction

The rate of decrease in NADH concentration is directly proportional to the alanine amino transfer activity in the sample.

LDH: Lactate Dehydrogenase

REAGENT COMPOSITION

| Reagent 1 | Buffer Tris pH 7.5 à 30°C | 100 mmol/l |
|------------------------|-----------------------------|-------------------------------------|
| Buffer | Alanine | 500 mmol/l |
| Reagent 2 Substrate | NADH LDH Oxoglutarate | 0.18 mmo/l 1200 U/l 15 mmol/l |

SAFETY CAUTIONS

Biomaghreb reagents are intended for use by qualified personnel for in vitro use (do not pipette by mouth).

- · Refer to the current MSDS available on request or on www.biomaghreb.com.
- Check the integrity of the reagents before use.
- Disposal of waste: comply with applicable legislation.

For safety reasons, treat any specimen or reagent of biological origin as potentially infectious. Observe the applicable legislation.

REAGENT PREPARATION

Working solution:

Mix the substrate with 3 ml REF (11015) and REF (11039) or 10 ml REF (11022) of Buffer R1. For REF (11046) reconstitute each R2 with one vial R1.

SAMPLE COLLECTION AND HANDLING

Heparinized serum or plasma without hemolysis.

PRESERVATION AND STABILITY

Stored in the original, tightly stoppered bottle at 2-8°C, the reagents are stable if used and stored under the recommended conditions:

- Before opening: Until the expiry date indicated on the label of the box at +4°C;
- . After opening : (Working Solution):

24 hours at 20-25°C;

7 days at 2-8°C.

ADDITIONAL EQUIPMENT

- · Basic equipment of the medical analysis laboratory;
- · Spectrophotometer or Clinical Biochemistry Analyzer.

LIMITS

Hemolysis can interfere.

QUALITY CONTROL

External quality control program.

It is recommended to control in the following cases:

- · At least one test per series.
- . Change of reagent bottle.
- After maintenance work on the analyzer.

If a control value is outside the confidence limits, repeat the procedure using the same control. Use normal and pathological control sera.

LINEARITY

If the $\Delta DO/min$ at 340 nm is greater than 0.15, repeat the test by diluting the sample 1:10 with a 9 g/I NaCl solution.

Multiply the result by 10.

PROCEDURE

Wavelength: 340 nm:

Temperature: 25 - 30 or 37 ° C:

Tank: 1 cm thick:

Adjust the spectrophotometer zero to air or distilled water.

| Working solution | 1 ml | 3 ml | | | | |
|--|--------|--------|--|--|--|--|
| Pre-incubate at the selected temperature (25, 30 or 37°C). | | | | | | |
| Sample | 100 μΙ | 300 μΙ | | | | |
| Mix and incubate 1 minute. Measure the decrease in optical density per minute for 1 to 3 minutes. | | | | | | |

CALCULATION

At wavelength 340 nm $\Lambda DO / min \times 1750 = IU/I$

REFERENCE VALUES

| | 25°C | 30°C | 37°C |
|-------|---------------|---------------|--------------|
| Women | Up to 16 UI/I | Up to 22 UI/I | Up to 31UI/I |
| Men | Up to 22UI/I | Up to 29 UI/I | Up to 40UI/I |

REFERENCES

Bergmeyer H. Schaibe and Walefeld. Clin. Chem. 24 58 - 73 (1978);

Bergmeyer and Horder Clin. Chem. Acta 105 147 F (1980);

Henry R, J, et al., Am J clin Path (1960), 34, 381-398.





















Sufficient for < n > essais

Batch number

Manufacturer

In Vitro Diagnostic